Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

Rhea-AI Summary

Intellia Therapeutics (Nasdaq: NTLA) will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based gene editing therapy for hereditary angioedema, in a late-breaking oral session at the EAACI 2026 Congress in Istanbul.

A related poster will address treatment burdens for HAE patients in Europe.

News Market Reaction – NTLA

-2.42%

5 alerts

-2.42% Session close to close

-4.6% Trough in 24 hr 52 min

$1.89B Market Cap

0.2x Rel. Volume

In the Jun 1 session, NTLA declined 2.42%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights that Intellia secured a late-breaking oral slot at EAACI 2026 to showca...

Analysis

This announcement highlights that Intellia secured a late-breaking oral slot at EAACI 2026 to showcase additional Phase 3 HAELO data for lonvo-z in hereditary angioedema, plus a poster on patient burden outside the U.S. It follows earlier positive topline and durability data and ongoing regulatory interactions. Investors may watch for any new efficacy or safety details beyond the previously reported 87% attack reduction and 62% attack- and therapy-free rates, and how these shape the evolving BLA narrative.

Key Figures

EAACI 2026 dates: June 12–15, 2026 Oral presentation time: June 13, 2026; 8:45–9:45 a.m. TRT Poster presentation time: June 12, 2026; 12:00–1:00 p.m. TRT +2 more

5 metrics

EAACI 2026 dates June 12–15, 2026 European Academy of Allergy & Clinical Immunology Congress

Oral presentation time June 13, 2026; 8:45–9:45 a.m. TRT Late-breaking HAELO Phase 3 oral session

Poster presentation time June 12, 2026; 12:00–1:00 p.m. TRT HAE treatment burden poster session

Oral presentation number 100217 HAELO Phase 3 late-breaking talk identifier

Poster number D1.336 HAE burden poster identifier

Previous Clinical trial Reports

5 past events · Latest: Apr 27 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 27	Phase 3 HAELO topline	Positive	-4.3%	Reported strong Phase 3 HAELO efficacy and safety, plus rolling BLA initiation.
Apr 24	Topline readout timing	Neutral	-4.3%	Announced upcoming Phase 3 HAELO topline data and webcast scheduling details.
Mar 03	Longer-term HAE data	Positive	-11.9%	Presented durable Phase 1/2 lonvo-z data and HAE burden survey at AAAAI 2026.
Mar 02	MAGNITUDE hold lifted	Positive	+12.1%	FDA lifted clinical hold on MAGNITUDE Phase 3 ATTR-CM trial with safety mitigations.
Jan 27	MAGNITUDE-2 hold lifted	Positive	+6.3%	FDA lifted clinical hold on MAGNITUDE-2 ATTRv-PN trial and raised enrollment target.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial news for NTLA has produced mixed reactions, with several positive updates in HAE and ATTR met by negative or modest average moves of -0.44%, indicating that strong data have not consistently translated into immediate upside.

Recent Company History

Over recent months, Intellia has repeatedly highlighted clinical progress across lonvo-z and nex-z. Key events include positive Phase 3 HAELO topline data with an 87% HAE attack reduction and 62% of patients attack- and therapy-free, plus multiple FDA decisions lifting clinical holds on MAGNITUDE and MAGNITUDE-2 Phase 3 trials. Earlier AAAAI 2026 presentations showed durable, long-term HAE control. Today’s EAACI late-breaking lonvo-z data slot continues this pattern of maturing clinical evidence and regulatory engagement for its lead programs.

Key Terms

phase 3, randomised, double-blind, placebo-controlled, +2 more

6 terms

phase 3 medical

"HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomised medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

Randomised means participants or items are assigned to different groups by chance rather than choice, like flipping a coin to decide who gets which treatment or process. This matters to investors because it reduces bias and makes outcomes more reliable, helping separate real effects from luck so that claims about a product, treatment, or business change are more trustworthy when assessing risk and value.

double-blind medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

crispr-based gene editing therapy medical

"a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema"

A crispr-based gene editing therapy uses a molecular “scissor and guide” system to change a specific piece of DNA inside a patient’s cells, aiming to fix or disable a faulty gene that causes disease. Investors care because these treatments can transform or replace long-term care for certain conditions, offering large potential rewards but also high technical, regulatory and safety risks and long development timelines similar to betting on a breakthrough technology.

hereditary angioedema medical

"lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE)"

A rare inherited disorder that causes sudden, painful swelling under the skin or in internal tissues, including the airway, because a natural blood‑control protein is missing or not working. Attacks can be unpredictable and sometimes life‑threatening, so people often need ongoing medication or emergency treatment. For investors, hereditary angioedema represents a niche but stable market for specialized therapies, diagnostics, and emergency care solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.

Late-Breaking Oral Presentation Details:

• Title: HAELO, a Phase 3, Global, Randomised, Double-Blind, Placebo-Controlled Study of Lonvoguran Ziclumeran, a CRISPR-Based Gene Editing Therapy, in Patients with Hereditary Angioedema
  Session: Immune deficiencies and autoimmunity
  Data and Time: Saturday, June 13, 2026, from 8:45 – 9:45 a.m. TRT
  Presentation Number: 100217
  Presenter: Danny Cohn, M.D., Ph.D., Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam

Poster Presentation Details:

• Title: Barriers to Normalization with Existing Treatments Among People Living with Hereditary Angioedema in Europe
  Session: Immune deficiencies and autoimmunity 02
  Data and Time: Friday, June 12, 2026, from 12:00 – 1:00 p.m. TRT
  Poster Number: D1.336
  Presenter: Henriette Farkas, M.D., Ph.D., Professor of Allergy and Clinical Immunology Director of the Hungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Hematology, Semmelweis University

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose. Lonvo-z has received five notable regulatory designations: Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.

About Hereditary Angioedema
Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicommunications.com 

FAQ

What Phase 3 HAELO data for lonvo-z will Intellia (NTLA) present at EAACI 2026?

Intellia will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. According to Intellia, results will be shared in a late-breaking oral session focused on immune deficiencies and autoimmunity at EAACI 2026 in Istanbul.

When is Intellia Therapeutics’ late-breaking HAELO oral presentation on lonvo-z at EAACI 2026?

The late-breaking HAELO oral presentation is scheduled for Saturday, June 13, 2026, from 8:45–9:45 a.m. TRT. According to Intellia, the talk will occur in an immune deficiencies and autoimmunity session, with presentation number 100217 and Danny Cohn, M.D., Ph.D., as presenter.

Who will present Intellia’s Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) at EAACI 2026?

Danny Cohn, M.D., Ph.D., will present the Phase 3 HAELO oral data on lonvo-z. According to Intellia, he is an internist in the Department of Vascular Medicine at Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam.

What is lonvoguran ziclumeran (lonvo-z) being studied for in the Phase 3 HAELO trial?

Lonvoguran ziclumeran (lonvo-z) is being studied as a CRISPR-based gene editing therapy for hereditary angioedema. According to Intellia, the HAELO study is a global, randomized, double-blind, placebo-controlled Phase 3 trial in patients with hereditary angioedema.

What poster will Intellia (NTLA) present about hereditary angioedema at EAACI 2026?

Intellia will present a poster on barriers to normalization with existing hereditary angioedema treatments in Europe. According to Intellia, the poster focuses on burdens experienced by HAE patients living outside the United States and will be shown in an immune deficiencies and autoimmunity session.

When is Intellia’s hereditary angioedema poster session scheduled at EAACI 2026?

The hereditary angioedema poster session is scheduled for Friday, June 12, 2026, from 12:00–1:00 p.m. TRT. According to Intellia, the poster is numbered D1.336 and will be presented in the Immune deficiencies and autoimmunity 02 session.

Who will present Intellia’s hereditary angioedema treatment burden poster at EAACI 2026?

Henriette Farkas, M.D., Ph.D., will present the hereditary angioedema treatment burden poster. According to Intellia, she is Professor of Allergy and Clinical Immunology and Director of the Hungarian Angioedema Center of Reference and Excellence at Semmelweis University.